Glooko, Inc. and Hedia have launched an innovative interoperable solution designed to improve diabetes management. The solution integrates connected care, remote patient monitoring, and digital therapeutic technologies to provide enhanced support for individuals with Type 1 and Type 2 diabetes who need advanced bolus insulin dosing.
A bolus is an additional dose of insulin taken to manage a rise in blood glucose levels, typically after eating a meal or snack. Generally, to correct high blood sugar, one unit of insulin can reduce blood glucose by 50 mg/dl. However, for those with diabetes who do not use an insulin pump, calculating the correct bolus dose can be a challenging task for both patients and their healthcare providers.
Glooko, a digital health company, has developed a solution to make this process easier and more accurate. The Glooko platform allows patients to seamlessly share their diabetes-related data, such as blood glucose readings, insulin doses, carbohydrate intake, exercise activity, blood pressure, and weight, with their healthcare providers. This solution enhances diabetes management by providing comprehensive insights into a patient’s daily health activities, making it easier to adjust treatment plans and improve health outcomes.
In partnership with Hedia, Glooko is introducing the Hedia Diabetes Assistant, which integrates with its platform to provide personalised insulin dose recommendations. This integration ensures that patients have real-time access to tailored bolus calculations, supporting more effective management of their diabetes. By considering various factors such as active insulin, food intake, physical activity, and blood glucose levels, the Hedia Diabetes Assistant generates insulin recommendations that will help stabilise blood glucose levels and simplify diabetes management.
This solution allows patients who are not using pumps to manage their insulin dosing effectively, providing them with personalized and actionable recommendations. The goal is to reduce the complexity of managing diabetes with multiple daily injections and ensure that patients can maintain consistent blood glucose control.
This partnership also benefits healthcare providers by giving them enhanced visibility into their patients’ health data. With easy access to key metrics such as blood glucose levels, insulin doses, carbohydrate intake, physical activity, and more, providers can make more informed decisions about a patient’s treatment plan.
Mike Alvarez, Chief Executive Officer of Glooko, commented, “We are very pleased to bring this algorithm-driven, personalized innovation to diabetes patients and their healthcare teams through our partnership with Hedia. With extensive clinical data supporting Hedia’s efficacy, this solution provides an alternative for those unable to access insulin pumps, ensuring more effective management of MDI therapy.”
Lars Christian Lund, Chief Executive Officer of Hedia, stated “This joint offering is perfectly aligned with Hedia’s vision to improve the quality of life for people with diabetes and make the best diabetes management tools available.”
Initially available in the United Kingdom, the solution will soon expand to other European countries.
To find out more, CLICK HERE.
